524717 — Titan Biotech Balance Sheet
0.000.00%
- IN₹3.91bn
- IN₹3.83bn
- IN₹1.64bn
- 92
- 22
- 35
- 49
Annual balance sheet for Titan Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | C2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 18.6 | 54.5 | 68.1 | 48.6 | 28.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 119 | 190 | 166 | 221 | 222 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 442 | 588 | 638 | 683 | 722 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 311 | 338 | 385 | 491 | 545 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 760 | 1,007 | 1,081 | 1,345 | 1,566 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 204 | 193 | 169 | 204 | 191 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 368 | 320 | 218 | 246 | 231 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 392 | 688 | 862 | 1,099 | 1,335 |
Total Liabilities & Shareholders' Equity | 760 | 1,007 | 1,081 | 1,345 | 1,566 |
Total Common Shares Outstanding |